MNLO dropped significantly on poor results for a Ph2 Atopic Dermatitis study during 4/18 There are mitigating circumstances: * It has recently reported positive Ph2s in two other indications * Two more Ph2s are pending. Cash on 12/31/17 was $62.5mn providing a runway thru 2018